<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Resistance to thyrotropin and thyrotropin-releasing hormone</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Resistance to thyrotropin and thyrotropin-releasing hormone</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Resistance to thyrotropin and thyrotropin-releasing hormone</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Samuel Refetoff, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Roy E Weiss, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Helmut Grasberger, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David S Cooper, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alison G Hoppin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 22, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Resistance to thyroid-stimulating hormone (RTSH) is characterized by elevated serum TSH of normal biologic activity in the absence of goiter. Affected patients may be euthyroid or hypothyroid. It is caused by one of several genetic defects that impair function of the TSH receptor.</p><p>Resistance to thyrotropin-releasing hormone (TRH) is a rare disorder that manifests as central hypothyroidism. It is caused by inactivating mutations in the TRH receptor (<em>TRHR</em>) gene.</p><p>The syndromes of resistance to thyrotropin (TSH) and resistance to TRH will be discussed here. Disorders of reduced sensitivity to thyroid hormone, including resistance to thyroid hormone, are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5827.html" rel="external">"Resistance to thyroid hormone and other defects in thyroid hormone action"</a> and  <a class="medical medical_review" href="/z/d/html/132665.html" rel="external">"Genetic defects in thyroid hormone transport and metabolism"</a>.)</p><p class="headingAnchor" id="H2329779984"><span class="h1">GENERAL MECHANISMS OF HORMONE RESISTANCE SYNDROMES</span><span class="headingEndMark"> — </span>Hormone resistance syndromes can be broadly defined as reduced or absent end-organ responsiveness to a hormone. Several general mechanisms have been identified:</p><p class="bulletIndent1"><span class="glyph">●</span>Impaired biologic activity of the hormone – Impaired activity of the hormone is caused by mutations or post-transcriptional modifications that result in production of an abnormal hormone molecule. Since response to the authentic hormone is normal, this circumstance is a "pseudo-resistance."</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Impaired function of hormone receptor – Impaired receptor function is caused by mutations in the receptor gene, leading in defective or absent receptor protein. Receptor defects result in impaired or absent ability to bind the hormone, defective transmission of the signal produced by hormone binding, defective targeting to the site of action, or lack of receptor synthesis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Quantitative reduction in receptor in the absence of receptor gene defect – Reduced quantity of the receptor may be caused by decreased synthesis or accelerated degradation. These can occur in an absence of a defect in the receptor gene or molecule proper but involve substances that control such functions.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Post-receptor abnormalities – Cell membrane hormone receptors, such as the thyrotropin (thyroid-stimulating hormone [TSH]) receptor, mediate hormone action by activating second messengers through interaction with guanine nucleotide-binding (Gs or Gq) proteins. Because these second messengers are activated by multiple hormones, some defects in post-receptor signaling pathways can give rise to impaired action of several hormones, as is the case in McCune-Albright syndrome. (See  <a class="medical medical_review" href="/z/d/html/5812.html" rel="external">"Definition, etiology, and evaluation of precocious puberty", section on 'McCune-Albright syndrome'</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">RESISTANCE TO THYROID-STIMULATING HORMONE</span><span class="headingEndMark"> — </span>Resistance to thyroid-stimulating hormone (RTSH) is broadly characterized by high serum TSH (hyperthyrotropinemia) with normal TSH biologic activity, in the absence of goiter.</p><p>Affected individuals have normal or hypoplastic thyroid glands, high serum TSH concentrations, and normal or low serum thyroxine (T4) and triiodothyronine (T3) concentrations. They are often identified at birth through neonatal screening for congenital hypothyroidism. (See  <a class="medical medical_review" href="/z/d/html/5836.html" rel="external">"Clinical features and detection of congenital hypothyroidism"</a>.)</p><p class="headingAnchor" id="H3"><span class="h2">Mechanism of TSH action</span><span class="headingEndMark"> — </span>TSH is the predominant regulator of thyroid growth and T4 and T3 synthesis and secretion. These actions are mediated through TSH-binding to the TSH receptor located on the plasma membrane of thyroid follicular cells. Activation of the TSH receptor results in activation of G proteins and then of the adenylyl cyclase-cyclic AMP pathway of signal transduction  (<a class="graphic graphic_figure graphicRef63929" href="/z/d/graphic/63929.html" rel="external">figure 1</a>). At higher concentrations of TSH, the phospholipase C-phosphatidylinositol pathway is activated. The result is stimulation of thyroid follicular cell growth and function [<a href="#rid1">1</a>].</p><p>The TSH receptor belongs to a superfamily of G protein-coupled receptors that have an extracellular amino-terminal domain, seven transmembrane segments, and a cytoplasmic carboxyl terminus [<a href="#rid2">2</a>]. It has some constitutive activity, so that thyroid function does not cease entirely in the absence of TSH. Expression of the TSH receptor gene is under the control of several factors, including thyroid transcription factor 1 (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F600635&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyqXw4MBVFnwUMkILj5DYDni&amp;TOPIC_ID=5845" target="_blank"><i>TTF1</i></a>, also known as <em>NKX2-1</em>), thyroid transcription factor 2 (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F602617&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyrsFAyXNiVs5OP%2FRpinw%2FPr&amp;TOPIC_ID=5845" target="_blank"><i>TTF2</i></a>, also known as <em>FOXE1</em>), and <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F167415&amp;token=tEpDslnpc0F0kICl%2Fz7sFQZkXc5y3Ni5EtCdXl4313XmuBHId1UyFToV7HQ6iBRY&amp;TOPIC_ID=5845" target="_blank"><i>PAX8</i></a> [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H4"><span class="h2">Prevalence and inheritance</span><span class="headingEndMark"> — </span>The precise prevalence of RTSH is not known. However, partial RTSH must not be uncommon as one-third of infants born in the state of Illinois with high blood TSH levels (&gt;30 mU/L) maintain normal levels of T4 (&gt;8 mcg/dL) and ongoing elevations of TSH when measured two to three weeks later (from the records of the Illinois State Laboratory) (see  <a class="medical medical_review" href="/z/d/html/5836.html" rel="external">"Clinical features and detection of congenital hypothyroidism", section on 'High TSH, normal free T4 or total T4'</a>). RTSH is inherited in either an autosomal recessive [<a href="#rid4">4</a>] or dominant manner [<a href="#rid5">5</a>].</p><p class="headingAnchor" id="H5"><span class="h2">Pathogenesis of RTSH</span><span class="headingEndMark"> — </span>Three genetic causes of RTSH have been so far identified. They involve two distinct genes and linkage to a gene locus [<a href="#rid4">4</a>].</p><p class="headingAnchor" id="H6"><span class="h3">Inactivating mutations in the TSH receptor gene located on chromosome 14</span><span class="headingEndMark"> — </span>This disorder was first described in 1995 [<a href="#rid6">6</a>]. The precise number of families with this defect is unknown but is likely in the thousands, involving approximately 100 different mutations [<a href="#rid7">7,8</a>]. A <a class="external" href="/external-redirect?target_url=https%3A%2F%2Ftsh-receptor-mutation-database.org%2F&amp;token=KT9eK1iazukGFRk%2FhtmY8AslY7RgP14lZY6h0MvqDQZ2Qi8Cjs0d01j3n1XCQxN3pag4ITl4auKr8OJPD5xZ7A%3D%3D&amp;TOPIC_ID=5845" target="_blank">TSHR mutation database</a> that is periodically updated is available. The inheritance is mostly recessive, equally split between homozygous and compound heterozygous gene mutations [<a href="#rid7">7</a>]. Decreased action of TSH results in reduced T4 and T3 synthesis and secretion, with compensatory increase in TSH secretion. The absence of goiter and the presence of thyroid hypoplasia in these patients are compatible with the dominant role of TSH on the growth of the thyroid gland [<a href="#rid9">9</a>]. Though not uncommon, TSH receptor gene mutations rarely cause severe congenital hypothyroidism [<a href="#rid10">10</a>]. To a certain degree, the magnitude of serum TSH elevation and the thyroid status of the patient vary with the severity of the functional impairment of the mutant TSH receptor.</p><p>With some of the mutations, heterozygotes may have higher serum TSH values, on average, usually in the upper limit of normal or just above normal [<a href="#rid11">11</a>]. In one series, 20 percent of young subjects with nonautoimmune hyperthyrotropinemia were heterozygotes for inactivating mutations of the TSH receptor [<a href="#rid7">7</a>]. In a sampling of a Japanese population, the frequency of heterozygous mutations of the TSH receptor was approximately 1:172 and the prevalence of homozygotes was approximately 1:118,000 [<a href="#rid12">12</a>]. The mild RTSH in individuals heterozygous for <em>TSHR</em> gene mutations is a dominant negative effect, due to entrapment of the normal receptor by oligomerization with the mutant [<a href="#rid13">13</a>]. A complex phenotype of congenital hypothyroidism and pseudohypoparathyroidism has been described in the presence of a combination of inactivating mutations of the TSH receptor and mutations of the downstream G protein (GNAS) [<a href="#rid14">14</a>].</p><p>Most loss-of-function mutations in the TSH receptor that have been identified are located in the extracellular domain of the TSH receptor, in contrast to the gain-of-function mutations that cause hyperthyroidism, which are located principally in the transmembrane and intracellular domains of the receptor [<a href="#rid15">15</a>]. Approximately one-half of the mutant TSH receptors have partial impairment of function, and in one-third of cases, affected subjects could maintain a euthyroid state by an appropriate increase in serum TSH levels (fully compensated RTSH).</p><p class="headingAnchor" id="H7"><span class="h3">PAX8 gene mutations located on chromosome 2</span><span class="headingEndMark"> — </span>Although the first reported cases of <em>PAX8</em> gene mutations were associated with thyroid dysgenesis [<a href="#rid16">16</a>], these mutations also can cause RTSH. Patients often are indistinguishable clinically and by thyroid tests from those with loss-of-function mutations in the TSH receptor gene [<a href="#rid17">17</a>]. Inheritance is autosomal dominant. The impaired association of the mutant PAX8 with other transcription factors regulating the TSH receptor, thyroglobulin, and thyroperoxidase genes appear to be responsible for the RTSH phenotype.</p><p class="headingAnchor" id="H8"><span class="h3">Defect in the long arm of chromosome 15</span><span class="headingEndMark"> — </span>Some patients with similar clinical findings have no detectable TSH receptor or <em>PAX8</em> gene mutations, nor do they have inactivating mutations in G protein [<a href="#rid5">5,18,19</a>]. The defect is inherited in an autosomal dominant manner. Although the precise cause of their RTSH is not known, it is linked to a 2.9 Megabase interval on chromosome 15q25.3-26.1 [<a href="#rid20">20</a>].</p><p class="headingAnchor" id="H9"><span class="h2">Classification and clinical manifestations</span><span class="headingEndMark"> — </span>RTSH should be suspected in patients, particularly infants, who have high serum TSH concentrations, normal or low serum free T4 and T3 concentrations, and a normally located thyroid gland.</p><p>Three phenotypes of resistance to TSH have been identified, representing different degrees of resistance to TSH. In subjects with TSH receptor gene defects, the phenotype correlates with the magnitude of functional impairment of the mutant TSH receptor  (<a class="graphic graphic_figure graphicRef79922" href="/z/d/graphic/79922.html" rel="external">figure 2</a>). This does not appear to be the case in RTSH caused by <em>PAX8</em> gene mutations and those linked to the locus on chromosome 15. In such individuals, wide variations in both TSH and free T4 and T3 are observed in affected individuals with the same mutation and within the same family  (<a class="graphic graphic_figure graphicRef79922" href="/z/d/graphic/79922.html" rel="external">figure 2</a>) [<a href="#rid5">5,17,20</a>].</p><p class="headingAnchor" id="H10"><span class="h3">Fully compensated defect</span><span class="headingEndMark"> — </span>The impaired response to TSH is compensated by hypersecretion of TSH; this overcomes the resistance, resulting in euthyroid hyperthyrotropinemia. In an individual patient with a mutation causing resistance to TSH, the phenotype tends to be stable over time. This course contrasts to that of acquired subclinical hypothyroidism (SCH) due to autoimmune thyroiditis, which, in the presence of antithyroid antibodies, tends to worsen over time.</p><p class="headingAnchor" id="H11"><span class="h3">Partially compensated defect</span><span class="headingEndMark"> — </span>This occurs when the high serum TSH cannot fully compensate for the defect; affected individuals have mild hypothyroidism. This most often occurs in patients who are homozygous for the TSH receptor mutation, who may be euthyroid initially (elevated TSH with normal free T4; compensated RTSH) but often develop hypothyroidism over time (partially compensated RTSH) [<a href="#rid21">21</a>].</p><p class="headingAnchor" id="H12"><span class="h3">Uncompensated defect</span><span class="headingEndMark"> — </span>Complete lack of TSH receptor function results in severe hypothyroidism. This most often occurs when both alleles carry mutant TSH receptors with complete lack of function [<a href="#rid9">9,22,23</a>].</p><p class="headingAnchor" id="H13"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>RTSH should be suspected in patients, particularly infants, who have high serum TSH concentrations, normal or low serum free T4 and T3 concentrations, and a normally located thyroid gland. The differential diagnosis includes all of those conditions that mildly impair thyroid hormone synthesis such as <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F167415&amp;token=tEpDslnpc0F0kICl%2Fz7sFQZkXc5y3Ni5EtCdXl4313XmuBHId1UyFToV7HQ6iBRY&amp;TOPIC_ID=5845" target="_blank"><i>PAX8</i></a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F600635&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyqXw4MBVFnwUMkILj5DYDni&amp;TOPIC_ID=5845" target="_blank"><i>TTF1</i></a><em> </em>(<em>NKX2-1</em>), <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F606759&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyqHmrwkY3dJBlsyOlif6yDM&amp;TOPIC_ID=5845" target="_blank"><i>DUOX2</i></a>, <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F612772&amp;token=tEpDslnpc0F0kICl%2Fz7sFSbCnKy1I6QPXy4E96e7Dz5x1MdmtaVf4ceOef1NUodC&amp;TOPIC_ID=5845" target="_blank"><i>DUOXA2</i></a>, and Pendrin (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.omim.org%2Fentry%2F605646&amp;token=tEpDslnpc0F0kICl%2Fz7sFUfdC7kgbt7z3sRDeh8bdyoxVuQDASrm8WKfNVcuNKXr&amp;TOPIC_ID=5845" target="_blank"><i>SLC26A4</i></a>) gene mutations [<a href="#rid4">4,24,25</a>]. Because of the important role of TSH in promoting thyroid growth, RTSH is unlikely if the patient has a goiter or ectopically located thyroid tissue. (See  <a class="medical medical_review" href="/z/d/html/5836.html" rel="external">"Clinical features and detection of congenital hypothyroidism"</a> and  <a class="medical medical_review" href="/z/d/html/7886.html" rel="external">"Disorders that cause hypothyroidism"</a>.)</p><p class="headingAnchor" id="H3988265948"><span class="h3">Subclinical hypothyroidism</span><span class="headingEndMark"> — </span>SCH is included in the differential diagnosis of compensated RTSH (see  <a class="medical medical_review" href="/z/d/html/7883.html" rel="external">"Subclinical hypothyroidism in nonpregnant adults"</a>). Both compensated RTSH and SCH have slight to mild elevations of TSH and normal free T4 and T3 concentrations. By definition, patients with SCH are "subclinical" and typically do not have symptoms, just as patients with compensated RTSH do not usually have symptoms of hypothyroidism. In adults, the most common cause of this phenotype is autoimmune thyroid disease, in which case, the elevations of TSH reflects a mild state of hypothyroidism for that individual, although free T4 concentrations are within the normal range for the general population. By contrast, in patients with compensated RTSH, the elevated TSH is caused by reduced action of a normal TSH molecule, eg, due to mutations in the TSH receptor. This is more likely in children or in families with a history of a similar phenotype. (See <a class="local">'Pathogenesis of RTSH'</a> above.)</p><p>The presence of a mutation in a gene known to cause RTSH would distinguish the two conditions. However, since the prevalence of SCH is 4 to 15 percent of the population, it would not be practical to recommend genetic testing for all patients diagnosed with SCH. Nevertheless, it is important to distinguish these two conditions as diagnosis of compensated RTSH does not require treatment with LT4, while many argue that SCH should be treated, depending on the patient's age and level of elevation of the TSH. Therefore, we suggest genetic testing for suspected RTSH in patients with the following characteristics:</p><p class="bulletIndent1"><span class="glyph">●</span>Absence of a history of prior normal thyroid function tests</p><p class="bulletIndent1"><span class="glyph">●</span>Presence of RTSH phenotype in other family members (eg, familial occurrence without thyroid enlargement)</p><p class="bulletIndent1"><span class="glyph">●</span>Identification of thyroid hormone abnormalities during infancy or childhood (since SCH is not common in children)</p><p></p><p class="headingAnchor" id="H2296478685"><span class="h3">Other</span><span class="headingEndMark"> — </span>Other diagnoses that should be considered in patients with biochemical characteristics consistent with RTSH (slightly elevated TSH concentration and normal free T4 and T3 concentrations) include:</p><p class="bulletIndent1"><span class="glyph">●</span>Presence of <strong>human anti-mouse antibodies (HAMA)</strong> that can cause an elevated TSH with normal thyroid hormone levels. This possibility can be excluded by direct radioimmunoassay measurement after removal of suspected HAMA from the assay.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Presence of <strong>macro-TSH</strong>, which is a large molecular weight, biologically inactive TSH species, in which TSH is complexed with immunoglobulin G (IgG). While the free T4 and T3 values are normal, TSH is high. Other tests to diagnose macro-TSH include a blunted free T3 response to TRH stimulation and the use of free T4 cutoff values for a specific TSH value [<a href="#rid8">8</a>]. Confirmation of macro-TSH can be made either by column chromatography, in which the TSH peak is eluted in the void volume and thus indicates a high molecular weight, or by polyethylene glycol precipitation [<a href="#rid26">26</a>].</p><p></p><p>Several studies have examined the role of polymorphisms in the TSH receptor gene but have been unable to fully explain the wide range of normal TSH concentrations in the "normal population." One study has shown that 13 of 116 adults with SCH but without evidence of autoimmune thyroid disease were heterozygous for TSH receptor gene mutations, most of which were proven to result in loss of function [<a href="#rid27">27</a>].</p><p class="headingAnchor" id="H14"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>Individuals with fully compensated RTSH are euthyroid and need no treatment [<a href="#rid21">21</a>]. There is no evidence that in the absence of other risk factors, persistent elevation of serum TSH levels produces TSH-secreting pituitary adenomas or thyroid neoplasia.</p><p>Individuals with mutations in both alleles of the TSH receptor may be euthyroid initially (elevated TSH with normal free T4; compensated RTSH) but often develop mild hypothyroidism over time (partially compensated RTSH) [<a href="#rid21">21</a>]. Individuals with partially compensated or uncompensated RTSH should be treated with <a class="drug drug_general" data-topicid="9557" href="/z/d/drug information/9557.html" rel="external">levothyroxine</a>, like any other hypothyroid patient. Because these individuals have normal responsiveness to thyroid hormone, the goal is to normalize their serum TSH concentration.</p><p class="headingAnchor" id="H15"><span class="h1">RESISTANCE TO THYROTROPIN-RELEASING HORMONE</span><span class="headingEndMark"> — </span>Resistance to thyrotropin-releasing hormone (TRH) is a rare disorder that is transmitted as an autosomal recessive trait. It is due to an inactivating mutation in the TRH receptor.</p><p class="headingAnchor" id="H16"><span class="h2">Mechanism of action of thyrotropin-releasing hormone</span><span class="headingEndMark"> — </span>TRH, a tripeptide of hypothalamic origin, acts by binding to TRH receptors located on the cell membranes of the pituitary thyrotroph cells. This results in depolarization, an influx of calcium into the cytosol, and activation of the phospholipase C-phosphatidylinositol pathway that stimulates the synthesis and release of thyroid-stimulating hormone (TSH) [<a href="#rid28">28</a>].</p><p>The human TRH gene is located on chromosome 3 and contains six copies of the progenitor sequence [<a href="#rid29">29</a>]. The TRH receptor, a typical G protein-coupled receptor with seven transmembrane spanning domains, is encoded by a single gene located on chromosome 8 [<a href="#rid28">28,30</a>].</p><p class="headingAnchor" id="H17"><span class="h2">Pathogenesis</span><span class="headingEndMark"> — </span>Resistance to TRH is due to inactivating mutations in the TRH receptor (<em>TRHR</em>) gene. This disorder was first described in 1997 in a child with compound heterozygote mutations [<a href="#rid31">31</a>]. Twelve years passed before a second family with resistance to TRH was reported; affected members were homozygous for a different <em>TRHR</em> mutation [<a href="#rid32">32</a>]. Heterozygotes are normal.</p><p class="headingAnchor" id="H18"><span class="h2">Clinical manifestations</span><span class="headingEndMark"> — </span>The patient with resistance to TRH presented with findings of central hypothyroidism: normal serum TSH, low thyroxine (T4) and triiodothyronine (T3) concentrations, and no serum TSH or prolactin responses to the administration of TRH. (See  <a class="medical medical_review" href="/z/d/html/7849.html" rel="external">"Central hypothyroidism"</a>.)</p><p class="headingAnchor" id="H19"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Resistance to thyroid-stimulating hormone (RTSH)</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Definition</strong> – RTSH is characterized by high serum TSH (hyperthyrotropinemia) with normal TSH biologic activity, in the absence of goiter. It is caused by one of several genetic defects that impair function of the TSH receptor. (See <a class="local">'Resistance to thyroid-stimulating hormone'</a> above and <a class="local">'Pathogenesis of RTSH'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Clinical manifestations</strong> – RTSH should be suspected in patients, particularly infants, who have high serum TSH concentrations, normal or low serum thyroxine (T4), free T4, and triiodothyronine (T3) concentrations, and a normally located thyroid gland that is normal size or hypoplastic. The phenotype varies depending on the degree of resistance to TSH. (See <a class="local">'Classification and clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pathogenesis</strong> – RTSH has been associated with inactivating mutations in the TSH receptor gene (mostly autosomal recessive), or <em>PAX8</em> gene mutations (autosomal dominant). Other cases in which these mutations are absent have been linked to a region on the long arm of chromosome 15. (See <a class="local">'Pathogenesis of RTSH'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Treatment</strong> – In patients with RTSH who are euthyroid (the impaired response to TSH is fully compensated by hypersecretion of TSH), we suggest NOT treating with thyroid hormone (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). (See <a class="local">'Fully compensated defect'</a> above.)</p><p></p><p class="bulletIndent2">If the high serum TSH cannot fully compensate for the defect (partially compensated or uncompensated defects), the individual is hypothyroid and should be treated with thyroid hormone like any other hypothyroid patient. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Resistance to thyrotropin-releasing hormone (TRH)</strong> – Resistance to TRH is a very rare disorder that is transmitted as an autosomal recessive trait. It is due to an inactivating mutation in the TRH receptor and manifests as central hypothyroidism. (See <a class="local">'Resistance to thyrotropin-releasing hormone'</a> above.)</p><p></p><p class="headingAnchor" id="H799810064"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>Support for this topic review was provided in part with funds from the National Institutes of Health (NIH), USA grant 4R37 DK15070.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Allgeier A, Offermanns S, Van Sande J, et al. The human thyrotropin receptor activates G-proteins Gs and Gq/11. J Biol Chem 1994; 269:13733.</a></li><li><a class="nounderline abstract_t">Laugwitz KL, Allgeier A, Offermanns S, et al. The human thyrotropin receptor: a heptahelical receptor capable of stimulating members of all four G protein families. Proc Natl Acad Sci U S A 1996; 93:116.</a></li><li><a class="nounderline abstract_t">Damante G, Di Lauro R. Thyroid-specific gene expression. Biochim Biophys Acta 1994; 1218:255.</a></li><li><a class="nounderline abstract_t">Grasberger H, Refetoff S. Resistance to thyrotropin. Best Pract Res Clin Endocrinol Metab 2017; 31:183.</a></li><li><a class="nounderline abstract_t">Grasberger H, Mimouni-Bloch A, Vantyghem MC, et al. Autosomal dominant resistance to thyrotropin as a distinct entity in five multigenerational kindreds: clinical characterization and exclusion of candidate loci. J Clin Endocrinol Metab 2005; 90:4025.</a></li><li><a class="nounderline abstract_t">Sunthornthepvarakui T, Gottschalk ME, Hayashi Y, Refetoff S. Brief report: resistance to thyrotropin caused by mutations in the thyrotropin-receptor gene. N Engl J Med 1995; 332:155.</a></li><li><a class="nounderline abstract_t">Persani L, Calebiro D, Cordella D, et al. Genetics and phenomics of hypothyroidism due to TSH resistance. Mol Cell Endocrinol 2010; 322:72.</a></li><li><a class="nounderline abstract_t">Ohba K, Maekawa M, Iwahara K, et al. Abnormal thyroid hormone response to TRH in a case of macro-TSH and the cut-off value for screening cases of inappropriate TSH elevation. Endocr J 2020; 67:125.</a></li><li><a class="nounderline abstract_t">Abramowicz MJ, Duprez L, Parma J, et al. Familial congenital hypothyroidism due to inactivating mutation of the thyrotropin receptor causing profound hypoplasia of the thyroid gland. J Clin Invest 1997; 99:3018.</a></li><li><a class="nounderline abstract_t">Ahlbom BD, Yaqoob M, Larsson A, et al. Genetic and linkage analysis of familial congenital hypothyroidism: exclusion of linkage to the TSH receptor gene. Hum Genet 1997; 99:186.</a></li><li><a class="nounderline abstract_t">Alberti L, Proverbio MC, Costagliola S, et al. Germline mutations of TSH receptor gene as cause of nonautoimmune subclinical hypothyroidism. J Clin Endocrinol Metab 2002; 87:2549.</a></li><li><a class="nounderline abstract_t">Narumi S, Muroya K, Abe Y, et al. TSHR mutations as a cause of congenital hypothyroidism in Japan: a population-based genetic epidemiology study. J Clin Endocrinol Metab 2009; 94:1317.</a></li><li><a class="nounderline abstract_t">Calebiro D, de Filippis T, Lucchi S, et al. Intracellular entrapment of wild-type TSH receptor by oligomerization with mutants linked to dominant TSH resistance. Hum Mol Genet 2005; 14:2991.</a></li><li><a class="nounderline abstract_t">Lado-Abeal J, Castro-Piedras I, Palos-Paz F, et al. A family with congenital hypothyroidism caused by a combination of loss-of-function mutations in the thyrotropin receptor and adenylate cyclase-stimulating G alpha-protein subunit genes. Thyroid 2011; 21:103.</a></li><li><a class="nounderline abstract_t">Van Sande J, Parma J, Tonacchera M, et al. Somatic and germline mutations of the TSH receptor gene in thyroid diseases. J Clin Endocrinol Metab 1995; 80:2577.</a></li><li><a class="nounderline abstract_t">Macchia PE, Lapi P, Krude H, et al. PAX8 mutations associated with congenital hypothyroidism caused by thyroid dysgenesis. Nat Genet 1998; 19:83.</a></li><li><a class="nounderline abstract_t">Grasberger H, Ringkananont U, Lefrancois P, et al. Thyroid transcription factor 1 rescues PAX8/p300 synergism impaired by a natural PAX8 paired domain mutation with dominant negative activity. Mol Endocrinol 2005; 19:1779.</a></li><li><a class="nounderline abstract_t">Mimouni M, Mimouni-Bloch A, Schachter J, Shohat M. Familial hypothyroidism with autosomal dominant inheritance. Arch Dis Child 1996; 75:245.</a></li><li><a class="nounderline abstract_t">Xie J, Pannain S, Pohlenz J, et al. Resistance to thyrotropin (TSH) in three families is not associated with mutations in the TSH receptor or TSH. J Clin Endocrinol Metab 1997; 82:3933.</a></li><li><a class="nounderline abstract_t">Grasberger H, Vaxillaire M, Pannain S, et al. Identification of a locus for nongoitrous congenital hypothyroidism on chromosome 15q25.3-26.1. Hum Genet 2005; 118:348.</a></li><li><a class="nounderline abstract_t">Tenenbaum-Rakover Y, Almashanu S, Hess O, et al. Long-term outcome of loss-of-function mutations in thyrotropin receptor gene. Thyroid 2015; 25:292.</a></li><li><a class="nounderline abstract_t">Gagné N, Parma J, Deal C, et al. Apparent congenital athyreosis contrasting with normal plasma thyroglobulin levels and associated with inactivating mutations in the thyrotropin receptor gene: are athyreosis and ectopic thyroid distinct entities? J Clin Endocrinol Metab 1998; 83:1771.</a></li><li><a class="nounderline abstract_t">Tiosano D, Pannain S, Vassart G, et al. The hypothyroidism in an inbred kindred with congenital thyroid hormone and glucocorticoid deficiency is due to a mutation producing a truncated thyrotropin receptor. Thyroid 1999; 9:887.</a></li><li><a class="nounderline abstract_t">Srichomkwun P, Takamatsu J, Nickerson DA, et al. DUOX2 Gene Mutation Manifesting as Resistance to Thyrotropin Phenotype. Thyroid 2017; 27:129.</a></li><li><a class="nounderline abstract_t">Kühnen P, Turan S, Fröhler S, et al. Identification of PENDRIN (SLC26A4) mutations in patients with congenital hypothyroidism and "apparent" thyroid dysgenesis. J Clin Endocrinol Metab 2014; 99:E169.</a></li><li><a class="nounderline abstract_t">Hattori N, Ishihara T, Yamagami K, Shimatsu A. Macro TSH in patients with subclinical hypothyroidism. Clin Endocrinol (Oxf) 2015; 83:923.</a></li><li><a class="nounderline abstract_t">Camilot M, Teofoli F, Gandini A, et al. Thyrotropin receptor gene mutations and TSH resistance: variable expressivity in the heterozygotes. Clin Endocrinol (Oxf) 2005; 63:146.</a></li><li><a class="nounderline abstract_t">Gershengorn MC, Osman R. Molecular and cellular biology of thyrotropin-releasing hormone receptors. Physiol Rev 1996; 76:175.</a></li><li><a class="nounderline abstract_t">Wilber JF, Feng P, Li QL, Shi ZX. The thyrotropin-releasing hormone gene: differential regulation, expression, and function in hypothalamus and two unexpected extrahypothalamic loci, the heart and testis. Trends Endocrinol Metab 1996; 7:93.</a></li><li><a class="nounderline abstract_t">Hinuma S, Hosoya M, Ogi K, et al. Molecular cloning and functional expression of a human thyrotropin-releasing hormone (TRH) receptor gene. Biochim Biophys Acta 1994; 1219:251.</a></li><li><a class="nounderline abstract_t">Collu R, Tang J, Castagné J, et al. A novel mechanism for isolated central hypothyroidism: inactivating mutations in the thyrotropin-releasing hormone receptor gene. J Clin Endocrinol Metab 1997; 82:1561.</a></li><li><a class="nounderline abstract_t">Bonomi M, Busnelli M, Beck-Peccoz P, et al. A family with complete resistance to thyrotropin-releasing hormone. N Engl J Med 2009; 360:731.</a></li></ol></div><div id="topicVersionRevision">Topic 5845 Version 16.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8188646" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : The human thyrotropin receptor activates G-proteins Gs and Gq/11.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8552586" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The human thyrotropin receptor: a heptahelical receptor capable of stimulating members of all four G protein families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8049251" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Thyroid-specific gene expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28648507" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Resistance to thyrotropin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15870119" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Autosomal dominant resistance to thyrotropin as a distinct entity in five multigenerational kindreds: clinical characterization and exclusion of candidate loci.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7528344" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Brief report: resistance to thyrotropin caused by mutations in the thyrotropin-receptor gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20083154" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Genetics and phenomics of hypothyroidism due to TSH resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31645528" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Abnormal thyroid hormone response to TRH in a case of macro-TSH and the cut-off value for screening cases of inappropriate TSH elevation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9185526" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Familial congenital hypothyroidism due to inactivating mutation of the thyrotropin receptor causing profound hypoplasia of the thyroid gland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9048917" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Genetic and linkage analysis of familial congenital hypothyroidism: exclusion of linkage to the TSH receptor gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12050212" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Germline mutations of TSH receptor gene as cause of nonautoimmune subclinical hypothyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19158199" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : TSHR mutations as a cause of congenital hypothyroidism in Japan: a population-based genetic epidemiology study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16135555" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Intracellular entrapment of wild-type TSH receptor by oligomerization with mutants linked to dominant TSH resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21186955" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : A family with congenital hypothyroidism caused by a combination of loss-of-function mutations in the thyrotropin receptor and adenylate cyclase-stimulating G alpha-protein subunit genes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7673398" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Somatic and germline mutations of the TSH receptor gene in thyroid diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9590296" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : PAX8 mutations associated with congenital hypothyroidism caused by thyroid dysgenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15718293" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Thyroid transcription factor 1 rescues PAX8/p300 synergism impaired by a natural PAX8 paired domain mutation with dominant negative activity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8976668" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Familial hypothyroidism with autosomal dominant inheritance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9398691" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Resistance to thyrotropin (TSH) in three families is not associated with mutations in the TSH receptor or TSH.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16189712" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Identification of a locus for nongoitrous congenital hypothyroidism on chromosome 15q25.3-26.1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25557138" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Long-term outcome of loss-of-function mutations in thyrotropin receptor gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9589691" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Apparent congenital athyreosis contrasting with normal plasma thyroglobulin levels and associated with inactivating mutations in the thyrotropin receptor gene: are athyreosis and ectopic thyroid distinct entities?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10524567" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The hypothyroidism in an inbred kindred with congenital thyroid hormone and glucocorticoid deficiency is due to a mutation producing a truncated thyrotropin receptor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27821020" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : DUOX2 Gene Mutation Manifesting as Resistance to Thyrotropin Phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24248179" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Identification of PENDRIN (SLC26A4) mutations in patients with congenital hypothyroidism and "apparent" thyroid dysgenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25388002" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Macro TSH in patients with subclinical hypothyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16060907" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Thyrotropin receptor gene mutations and TSH resistance: variable expressivity in the heterozygotes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8592728" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Molecular and cellular biology of thyrotropin-releasing hormone receptors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18406732" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The thyrotropin-releasing hormone gene: differential regulation, expression, and function in hypothalamus and two unexpected extrahypothalamic loci, the heart and testis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7918619" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Molecular cloning and functional expression of a human thyrotropin-releasing hormone (TRH) receptor gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9141550" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A novel mechanism for isolated central hypothyroidism: inactivating mutations in the thyrotropin-releasing hormone receptor gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19213692" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : A family with complete resistance to thyrotropin-releasing hormone.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
